Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome.

BACKGROUND Short QT syndrome (SQTS) is a primary electrical disease of the heart associated with a high risk of sudden cardiac death. A gain-of-function in I(Kr), due to a mutation in KCNH2, underlies SQT1. OBJECTIVE This study sought to examine the cellular basis for arrhythmogenesis in an experimental model of SQT1 created using PD-118057, a novel I(Kr) agonist. METHODS Transmembrane action potentials were simultaneously recorded from epicardial, M, and endocardial regions of arterially perfused canine left ventricular (LV) wedge preparations, together with a pseudo-electrocardiogram. RESULTS PD-118057 (10 micromol/l) abbreviated the QT interval from 267 +/- 4 to 232 +/- 4 ms and increased transmural dispersion of repolarization (TDR) from 33.7 +/- 2.0 to 49.1 +/- 3.1 ms (P <.001). T-wave amplitude increased from 18.0% +/- 1.4% to 23.1% +/- 1.7% of R-wave amplitude (P =.027). Reversing the direction of activation of the LV wall (epicardial pacing) resulted in an increase in QT interval from 269 +/- 5 to 282 +/- 5 ms and an increase in TDR from 34.1 +/- 2.0 to 57.6 +/- 3.3 ms (P <.001) under baseline conditions. PD-118057 abbreviated the QT interval from 282 +/- 5 to 258 +/- 5 ms and produced a proportional decrease in effective refractory period (ERP). TDR increased from 57.6 +/- 3.3 to 77.6 +/- 4.3 ms (P <.001). Polymorphic ventricular tachycardia (pVT) was induced in 10 of 20 preparations with a single S(2) applied to epicardium. Quinidine (10 micromol/l) increased the ERP and QT interval, did not significantly alter TDR, and prevented induction of pVT in 5 of 5 preparations. CONCLUSION Our results suggest that a combination of ERP abbreviation and TDR amplification underlie the development of pVT in SQT1 and that quinidine prevents pVT principally by prolonging ERP.

[1]  G. Breithardt,et al.  Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome , 2007, Journal of cardiovascular electrophysiology.

[2]  Wei Zhou,et al.  Short QT syndrome: a case report and review of literature. , 2006, Resuscitation.

[3]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[4]  Jun Zhou,et al.  Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity , 2005, Molecular Pharmacology.

[5]  Michel Haissaguerre,et al.  Short QT syndrome: clinical findings and diagnostic-therapeutic implications. , 2006, European heart journal.

[6]  Charles Antzelevitch,et al.  Effect of Epicardial or Biventricular Pacing to Prolong QT Interval and Increase Transmural Dispersion of Repolarization: Does Resynchronization Therapy Pose a Risk for Patients Predisposed to Long QT or Torsade de Pointes? , 2003, Circulation.

[7]  G. Yan,et al.  Effect of Epicardial or Biventricular Pacing to Prolong QT Interval and Increase Transmural Dispersion of Repolarization , 2003 .

[8]  A. V. van Ginneken,et al.  Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.

[9]  I. Gussak,et al.  Short QT syndrome--5 years of progress. , 2005, Journal of electrocardiology.

[10]  I. Gussak,et al.  Short QT syndrome: mechanisms, diagnosis and treatment , 2005, Nature Clinical Practice Cardiovascular Medicine.

[11]  Charles Antzelevitch,et al.  Epicardial Activation of Left Ventricular Wall Prolongs QT Interval and Transmural Dispersion of Repolarization: Implications for Biventricular Pacing , 2004, Circulation.

[12]  N. Simionescu,et al.  The Cardiovascular System , 1983 .

[13]  Michel Haissaguerre,et al.  Short QT syndrome: pharmacological treatment. , 2004, Journal of the American College of Cardiology.

[14]  Charles Antzelevitch,et al.  Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. , 2007, American journal of physiology. Heart and circulatory physiology.

[15]  J. Brugada,et al.  Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.

[16]  Jonathan M. Cordeiro,et al.  Modulation of IKr inactivation by mutation N588K in KCNH2: A link to arrhythmogenesis in short QT syndrome , 2005 .

[17]  S. Priori,et al.  A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.

[18]  J. Brugada,et al.  ECG phenomenon of idiopathic and paradoxical short QT intervals. , 2002, Cardiac electrophysiology review.

[19]  C. Antzelevitch,et al.  Cellular Mechanisms Underlying the Development of Catecholaminergic Ventricular Tachycardia , 2005, Circulation.

[20]  Martin Borggrefe,et al.  Short QT Syndrome: A Familial Cause of Sudden Death , 2003, Circulation.

[21]  C. Antzelevitch,et al.  Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes , 2006, Journal of internal medicine.

[22]  F. Gaita,et al.  Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. , 2005, Heart rhythm.

[23]  Charles Antzelevitch,et al.  Amplified Transmural Dispersion of Repolarization as the Basis for Arrhythmogenesis in a Canine Ventricular-Wedge Model of Short-QT Syndrome , 2004, Circulation.

[24]  C. Antzelevitch,et al.  Short QT syndrome. Genotype-phenotype correlations. , 2005, Journal of electrocardiology.

[25]  Michel Haïssaguerre,et al.  Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac Death , 2007, Circulation.